8月31日 - ** PMV Pharmaceuticals（PMVP.O）股价在盘后交易中下跌13.2%，报1.05美元，该公司正计划进行股权融资
** 这家精准肿瘤学公司 (link) 已开始发行股票及配套认股权证和预先融资认股权证；交易规模未披露
** TD Cowen 担任独家簿记管理人
** 总部位于新泽西州普林斯顿的PMVP还宣布 (link)，其药物rezatapopt在铂类耐药/难治性卵巢癌的II期临床试验中，客观缓解率达46%
** 该公司预计将于2027年第一季度提交rezatapopt用于治疗卵巢癌的新药申请
** PMVP股价周一收跌0.8%，报1.21美元，年初至今累计下跌3%；公司流通股约为5346万股
** 据伦敦证券交易所集团（LSEG）数据显示，所有六位覆盖该股的分析师均持看涨态度；目标价中位数为4美元
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.